New research has shown that the cannabinoids CBC (Cannabichromene) and CBG (Cannabigerol) both exhibit anti-tumor properties, tested on human Gastrointestinal Cancer Cells.
In tests performed by Cannabics Pharmaceuticals (OTCQB: CNBX), at the company’s High Through-put Screening (HTS) facility in Israel, researchers screened the necrotic effects of a variety of cannabinoids on human Gastrointestinal cancer cells, in addition to other cancer types previously tested. CBC and CBG were both shown to induce significantly higher rates of necrosis in these cancer cells compared to other cannabinoids, thus strengthening previously obtained results.
Cannabics Pharmaceuticals is a U.S public company that is developing a platform which leverages novel drug-screening tools and artificial intelligence to create cannabinoid-based therapies for cancer that are more precise to a patient’s profile. By developing tools to assess effectiveness on a personalized basis, Cannabics is helping to move cannabinoids into the future of cancer therapy.
These findings further support previous research performed by the company, which has consistently shown differential anti-tumor effects when using a variety of cannabinoids (CBG, CBC) on human cancer cells, derived from both fresh biopsies and cell lines.
These preliminary findings could allow Cannabics Pharmaceuticals to offer in the future, pending further research, a more extensive and thorough personalized report for patients advising them on cannabinoid medicine therapy protocols in order to maximize positive outcomes.
Dr. Yaakov Waksman, the company’s head of cannabidiol research, said, “My working assumption is that these results show that a correlation may exist between a cannabinoid’s Topological Polar Surface Area (TPSA) value and its ability to induce anti-tumor activity, diminishing cancer cell’s viability rates. CBC and CBG, as neutral cannabinoids, were both found to have a TPSA value which allows the cannabinoid molecule to penetrate a cancer cell’s membrane, whereas their acidic form (CBCA and CBGA) – do not. This could explain the difference in anti-tumor activity rates demonstrated“.
Dr. Yaakov Waksman joined Cannabics, as Head of Cannabidiol Research, earlier this year. He is well known for his work at the Department of Natural Products, School of Pharmacy, Faculty of Medicine at The Hebrew University of Jerusalem. In his studies, Dr. Waksman has examined the effects of cannabinoids on the human immune system and discovered that Cannabidiol can prevent the production of TNF – a discovery that had both theoretical and practical implications. Tumor necrosis factor (TNF) is a cell signaling protein [cytokine] involved in systemic inflammation and acute phase reactin. TNF is produced by activated macrophages and promotes inflammation.
Dr. Eyal Ballan, CTO and Co-Founder of Cannabics, commented, “Gastrointestinal cancers are amongst the leading and most wide-spread causes of cancer-related deaths worldwide. We are intrigued by the results we have obtained in the lab, and our aim is to consider placing an emphasis on this organ system, and to further explore the differential anti-tumor properties of cannabinoids. We believe that these preliminary results vindicate our vision; which is to bring personalization into cannabinoid-based cancer treatments.“